ArticleNutrition & metabolism2026
Effects of synbiotic supplementation on metabolic profiles in children with obesity: a randomized double-blinded placebo-controlled trial.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The role of the gut microbiota in obesity-related metabolic diseases in the pediatric population.Pediatric endocrinology, diabetes, and metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundChildhood obesity is a global concern, associated with various metabolic complications. Gut microbiota dysbiosis has been implicated in its pathogenesis. Synbiotics may improve metabolic health by modulating gut microbiota.
objectiveTo evaluate the effects of synbiotic supplementation on lipid profiles, fasting blood glucose (FBG), insulin, and alanine aminotransferase (ALT) in children with obesity.
methodsThis randomized, double-blind, placebo-controlled trial (April 2024-June 2025), children aged 7–18 years with obesity received either a new freeze-dried synbiotic (10 g inulin from Thai Jerusalem artichoke plus Bifidobacterium animalis and Lactobacillus paracasei, 10⁷ CFU each) or a placebo (isocaloric maltodextrin) daily for 3 months. Both groups received the same lifestyle modification counseling. Anthropometric measurements, dietary intake, physical activity, and metabolic parameters were assessed at baseline and month 3.
resultsSixty children were enrolled; 57 completed the study. High-density lipoprotein cholesterol (HDL-C) significantly increased in the synbiotic group compared to controls [median change: 0.34 (-0.16, 1.35) vs. -0.84 (-1.35, -0.33) mg/dL, P = 0.001], after adjusting for baseline. No significant changes were observed in BMI z-score or other metabolic parameters. Furthermore, there were no significant differences in dietary intake or physical activity levels between groups at the 3-month follow-up.
conclusionsSynbiotic supplementation significantly improved HDL-C in children with obesity. These results suggest that synbiotics may serve as an adjunctive nutritional intervention for managing metabolic health in childhood obesity.
trial registrationhttps://www.thaiclinicaltrials.org/ (TCTR20240321005).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.